At its October 14, 2026 Annual Meeting, iBio, Inc. stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized common shares from 275 million to 500 million. The filing also notes approval of Amendment No. 1 to the 2023 Omnibus Incentive Plan, which updates the evergreen provision for share reserves through 2033. Additionally, shareholders elected two Class III directors and ratified the independent auditor. iBio, Inc. is a biotechnology company focused on developing cell therapies.
